Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses.
David M Bamberger, Betty L Herndon, Jeffrey Fitch...
https://pubmed.ncbi.nlm.nih.gov/12183241/Actively Recruiting
Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-11-02
60
Participants Needed
8
Research Sites
13 weeks
Total Duration
Researchers are evaluating the combination of cefazolin with ertapenem for treating methicillin-susceptible Staphylococcus aureus MSSA bacteremia, a serious bloodstream infection. This phase 2 randomized controlled trial explores whether adding ertapenem to cefazolin can improve clinical outcomes compared to cefazolin alone. MSSA bacteremia causes significant mortality, and current treatments have room for improvement, prompting this study as a sub-study of the SNAP trial. Participants will receive either ertapenem intravenously 1g daily infused over 2 hours for 5 days alongside cefazolin or a saline placebo infusion alongside cefazolin. The ertapenem targets a different bacterial protein than cefazolin, potentially enhancing treatment effectiveness. The study involves randomized assignment to one of two groups ertapenem plus cefazolin or placebo plus cefazolin. During the trial, participants will be assessed for clinical success by Day 5, and monitored up to 90 days for outcomes including blood culture clearance, clinical improvement, length of hospital stay, mortality, infections like C. difficile, and kidney injury. Safety monitoring includes tracking seizures and new bacterial colonization. Follow-up visits and evaluations will help researchers measure the impact of the combination therapy over time.
CONDITIONS
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
L
Lina Petrella
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Todd C. Lee MD MPH FIDSA
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive daily intravenous infusions of either ertapenem or saline placebo, alongside cefazolin, for five days.
Daily visits during treatment
Duration - Up to 90 days
Participants are monitored for clinical outcomes including infection clearance, improvement, adverse events, and overall health for up to 90 days after treatment.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
David M Bamberger, Betty L Herndon, Jeffrey Fitch...
https://pubmed.ncbi.nlm.nih.gov/12183241/H F Chambers, M Sachdeva
https://pubmed.ncbi.nlm.nih.gov/2345297/Matthew P Cheng, Alexander Lawandi, Guillaume Butler-Laporte...
https://pubmed.ncbi.nlm.nih.gov/32667982/Erlinda R Ulloa, Kavindra V Singh, Matthew Geriak...
https://pubmed.ncbi.nlm.nih.gov/31773134/George Sakoulas, Joshua Olson, Juwon Yim...
https://pubmed.ncbi.nlm.nih.gov/27572414/Sara E Cosgrove, Gloria A Vigliani, Vance G Fowler...
https://pubmed.ncbi.nlm.nih.gov/19207079/Steven Y C Tong, Jocelyn Mora, Asha C Bowen...
https://pubmed.ncbi.nlm.nih.gov/35717634/Sunish Shah, Lloyd G Clarke, Bonnie A Falcione...
https://pubmed.ncbi.nlm.nih.gov/41433510/Todd C. Lee MD MPH FIDSA
Lead Sponsor